Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase 11 study
1998

Comparing Chemotherapy Regimens for Lung Cancer

Sample size: 140 publication Evidence: low

Author Information

Author(s): E Baldini, C Tibaldi, A Ardizzoni, F Salvati, A AntiIIi, L Portalone, S Barbera, F Romano, F De Marinis, MR Migliorino, MA Noseda, U Borghini, M Crippa, G Ferrara, M Raimondi, M Fioretti, M Bandera, MC Pennucci, G Galeasso, GC Cacciani, G Lepidini, G Sunseri, C Lanfranco, M Rinaldi, R Lionetto, PF Conte, R Rosso

Primary Institution: National Institute of Cancer Research, Genova

Hypothesis

The study aims to evaluate the activity and toxicity of three different platinum-based chemotherapy regimens in patients with advanced non-small-cell lung cancer.

Conclusion

None of the chemotherapy combinations reached the level of activity considered to be of interest for further phase III trials.

Supporting Evidence

  • Response rates for MVP, PIN, and CaN were 14.3%, 16.7%, and 14% respectively.
  • The overall median survivals were 256, 269, and 243 days for MVP, PIN, and CaN.
  • Myelosuppression was the most frequent toxicity observed in the study.

Takeaway

Doctors tested three types of chemotherapy to see which works best for lung cancer, but none were good enough to continue using in larger studies.

Methodology

This was a multicentre randomized phase II trial comparing three chemotherapy regimens in chemotherapy-naive patients with advanced NSCLC.

Potential Biases

The study design minimized selection bias, but the central review of responses may have led to cancellations of some responses.

Limitations

The study's response rates were lower than those reported in previous single-institution phase II trials, and the majority of patients had stage IV disease.

Participant Demographics

The study included 140 chemotherapy-naive patients, predominantly men, with a median age of 62 years, and 67% had stage IV disease.

Statistical Information

Confidence Interval

95% CI 5.94-27.2% for MVP, 95% CI 7.4-30.2% for PIN, 95% CI 5.3-27.9% for CaN

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication